Stock listing
Frankfurt:2H51 Ocugen, Inc. Aktie
German listing (Frankfurt) of Ocugen, Inc. · home listing NASDAQ:OCGN
Follow Ocugen, Inc. into a list and get an email when it puts out news.
Share price · FWB:2H51
€0.655 EUR -0.042 (-6.0%)
Close on Nov 20, 2026
- Day range
- €0.655 – €0.655 EURNov 20, 2026
- Volume
- 15,050 sharesNov 20, 2026
- Market cap
- €222.2M EURAt the close on Nov 20, 2026 · price × 339.3M shares outstanding
- 52-week range
- €0.636 – €2.336 EURLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- €15,493 EURMedian day 5,650 shares · 7 days with no trades · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:OCGN · Home | $0.768 USD | +0.029 (+3.9%) | 6,186,721 | $0.710 | $0.820 | $0.710 | $0.739 | Close on Nov 20, 2026 |
| Frankfurt:2H51 | €0.655 EUR | -0.042 (-6.0%) | 15,050 | €0.655 | €0.655 | €0.655 | €0.697 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · FWB:2H51 · EUR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| €0.816 | +0.042 | +5.4% | €0.721 | €0.820 | €0.715 | 2,834 | |
| €0.774 | +0.011 | +1.4% | €0.800 | €0.859 | €0.773 | 332,696 | |
| €0.763 | +0.107 | +16.3% | €0.676 | €0.769 | €0.668 | 72,298 | |
| €0.656 | -0.006 | -0.9% | €0.656 | €0.656 | €0.656 | 4,350 | |
| €0.662 | +0.020 | +3.1% | €0.656 | €0.676 | €0.655 | 14,300 | |
| €0.642 | -0.053 | -7.6% | €0.655 | €0.704 | €0.639 | 14,300 | |
| €0.695 | -0.001 | -0.1% | €0.684 | €0.703 | €0.679 | 7,204 | |
| €0.696 | +0.013 | +1.9% | €0.686 | €0.696 | €0.685 | 6,000 | |
| €0.683 | +0.047 | +7.4% | €0.652 | €0.697 | €0.647 | 11,010 | |
| €0.636 | -0.057 | -8.2% | €0.661 | €0.662 | €0.636 | 11,000 | |
| €0.693 | -0.029 | -4.0% | €0.702 | €0.707 | €0.688 | 0 | |
| €0.722 | +0.023 | +3.3% | €0.716 | €0.725 | €0.712 | 1,000 | |
| €0.699 | -0.044 | -5.9% | €0.739 | €0.745 | €0.698 | 41,500 | |
| €0.743 | +0.019 | +2.6% | €0.700 | €0.748 | €0.698 | 1,000 | |
| €0.724 | +0.003 | +0.4% | €0.708 | €0.735 | €0.704 | 5,300 | |
| €0.721 | -0.021 | -2.8% | €0.747 | €0.750 | €0.718 | 0 | |
| €0.742 | -0.032 | -4.1% | €0.765 | €0.770 | €0.739 | 10,647 | |
| €0.774 | +0.005 | +0.7% | €0.796 | €0.810 | €0.772 | 63,800 | |
| €0.769 | -0.072 | -8.6% | €0.839 | €0.845 | €0.765 | 28,763 | |
| €0.841 | +0.018 | +2.2% | €0.846 | €0.852 | €0.841 | 147 | |
| €0.823 | -0.075 | -8.4% | €0.872 | €0.874 | €0.823 | 22,000 | |
| €0.898 | -0.044 | -4.7% | €0.899 | €0.899 | €0.891 | 10,000 | |
| €0.942 | +0.030 | +3.3% | €0.928 | €0.947 | €0.919 | 18,926 | |
| €0.912 | -0.017 | -1.8% | €0.913 | €0.923 | €0.909 | 1,000 | |
| €0.929 | +0.036 | +4.0% | €0.913 | €0.930 | €0.902 | 18,010 | |
| €0.893 | -0.018 | -2.0% | €0.893 | €0.893 | €0.893 | 1,760 | |
| €0.911 | +0.013 | +1.4% | €0.911 | €0.911 | €0.911 | 200 | |
| €0.898 | -0.008 | -0.9% | €0.956 | €0.956 | €0.895 | 26,500 | |
| €0.906 | +0.021 | +2.4% | €0.901 | €0.908 | €0.897 | 3,000 | |
| €0.885 | -0.031 | -3.4% | €0.915 | €0.915 | €0.882 | 5,500 | |
| €0.916 | +0.047 | +5.4% | €0.871 | €0.945 | €0.864 | 36,400 | |
| €0.869 | -0.011 | -1.3% | €0.870 | €0.871 | €0.869 | 1,423 | |
| €0.880 | -0.010 | -1.1% | €0.916 | €0.917 | €0.872 | 11,000 | |
| €0.890 | -0.032 | -3.5% | €0.890 | €0.890 | €0.890 | 0 | |
| €0.922 | +0.041 | +4.7% | €0.922 | €0.922 | €0.922 | 0 | |
| €0.881 | -0.009 | -1.0% | €0.889 | €0.898 | €0.871 | 8,605 | |
| €0.890 | +0.034 | +4.0% | €0.875 | €0.892 | €0.871 | 5,030 | |
| €0.856 | -0.008 | -0.9% | €0.856 | €0.856 | €0.856 | 0 | |
| €0.864 | -0.040 | -4.4% | €0.900 | €0.922 | €0.858 | 5,550 | |
| €0.904 | -0.002 | -0.2% | €0.892 | €0.925 | €0.890 | 13,400 | |
| €0.906 | +0.010 | +1.1% | €0.858 | €0.910 | €0.858 | 12,170 | |
| €0.896 | -0.042 | -4.5% | €0.979 | €0.995 | €0.889 | 14,350 | |
| €0.938 | -0.234 | -20.0% | €1.126 | €1.137 | €0.925 | 89,603 | |
| €1.172 | +0.018 | +1.6% | €1.172 | €1.172 | €1.172 | 0 | |
| €1.154 | +0.003 | +0.3% | €1.157 | €1.157 | €1.151 | 23,200 | |
| €1.151 | +0.012 | +1.1% | €1.157 | €1.157 | €1.149 | 2,000 | |
| €1.139 | -0.009 | -0.8% | €1.150 | €1.178 | €1.137 | 24,313 | |
| €1.148 | +0.012 | +1.1% | €1.139 | €1.162 | €1.133 | 3,950 | |
| €1.136 | +0.005 | +0.4% | €1.143 | €1.143 | €1.133 | 5 | |
| €1.131 | -0.037 | -3.2% | €1.158 | €1.169 | €1.124 | 5,650 | |
| €1.168 | -0.032 | -2.7% | €1.167 | €1.169 | €1.164 | 2,000 | |
| €1.200 | +0.025 | +2.1% | €1.200 | €1.203 | €1.194 | 2,600 | |
| €1.175 | -0.002 | -0.2% | €1.176 | €1.176 | €1.175 | 2,000 | |
| €1.177 | 0.000 | 0.0% | €1.177 | €1.177 | €1.177 | 0 | |
| €1.177 | -0.023 | -1.9% | €1.201 | €1.204 | €1.168 | 8,970 | |
| €1.200 | -0.081 | -6.3% | €1.184 | €1.214 | €1.163 | 38,032 | |
| €1.281 | +0.044 | +3.6% | €1.259 | €1.290 | €1.241 | 400 |
Splits
1 split · FWB:2H51 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-60 | Consolidation |
- Ticker
- Frankfurt:2H51
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Nov 10, 2026
Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
Latest earnings call · Nov 4, 2026
Ocugen (NASDAQ:OCGN) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 16 slides
Latest news
Ocugen Provides Business Update with Third Quarter 2026 Financial Results
Nov 4, 2026
Closed €0.763 (+16.3%) on Nov 4, 2026
Ocugen to Participate in Upcoming November Investor and Industry Conferences
Oct 29, 2026
Closed €0.695 (-0.1%) on Oct 29, 2026
Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
Oct 22, 2026
Closed €0.722 (+3.3%) on Oct 22, 2026
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Oct 14, 2026
Closed €0.774 (+0.7%) on Oct 14, 2026
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Oct 6, 2026
Closed €0.912 (-1.8%) on Oct 6, 2026
Ocugen to Participate in Upcoming Scientific Conferences
Sep 30, 2026
Closed €0.898 (-0.9%) on Sep 30, 2026
Ocugen to Participate in Upcoming October Investor and Industry Conferences
Sep 29, 2026
Closed €0.906 (+2.4%) on Sep 29, 2026
Ocugen, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 39 in the last 12 months · 276 in all · newest Nov 10, 2026 · oldest 2019
- Calls
- 23 calls with a replay · 23 with a transcript · latest Nov 4, 2026
- Decks
- 75 decks · latest Nov 4, 2026
Where Ocugen, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:OCGN · Home listing | NASDAQ | United States | USD |
| gettex:2H51 | gettex | Germany | EUR |
| Tradegate:2H51 | Tradegate | Germany | EUR |
| LS Exchange:A2PSZH | LS Exchange | Germany | EUR |
| BMV:OCGN | BMV | Mexico | MXN |
| Lang & Schwarz:A2PSZH | Lang & Schwarz | Germany | EUR |
| Frankfurt:2H51 · This page | Frankfurt | Germany | EUR |
| Stuttgart:2H51 | Stuttgart | Germany | EUR |
| Munich:2H51 | Munich | Germany | EUR |
| Dusseldorf:2H51 | Dusseldorf | Germany | EUR |
| BOATS:OCGN | BOATS | United States | USD |
| BIVA:OCGN | BIVA | Mexico | MXN |
| Hamburg:2H51 | Hamburg | Germany | EUR |
| Hanover:2H51 | Hanover | Germany | EUR |
| Xetra:2H51 | Xetra | Germany | EUR |
Valuation
EV/sales 37.3× against a median of 6.3×: 3rd lowest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $178.1M USD
- P/E
- Loss
- EV/sales
- 37.3×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- 88.5%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 1.47
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Ocugen, Inc. · NASDAQ:OCGN | US$260.6M | US$178.1M | n/a | 37.3× | n/a | n/a | n/a | n/a | 1.47 |
| Kyverna Therapeutics, Inc. · NASDAQ:KYTX | US$263.5M | US$117.8M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | 2.02 |
| PepGen Inc. · NASDAQ:PEPG | US$261.8M | US$172.6M | n/a | n/a | n/a | 2.5× | n/a | 0.1× | 1.11 |
| Altimmune, Inc. · NASDAQ:ALT | US$258.8M | US$28.73M | n/a | n/a | n/a | 0.6× | n/a | 0.1× | 1.55 |
| Prelude Therapeutics Incorporated · NASDAQ:PRLD | US$258.6M | US$136.2M | n/a | 6.3× | n/a | 2.1× | −247.1% | 0.1× | 1.48 |
| OBI Pharma, Inc. · TPEX:4174 | US$258.4M | US$243.3M | n/a | 154× | n/a | 5.7× | n/a | 0.0× | n/a |
| TransThera Sciences (Nanjing). Inc. · HKEX:2617 | US$257.1M | US$119.1M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Eikon Therapeutics, Inc. · NASDAQ:EIKN | US$256.8M | US$44.67M | n/a | n/a | n/a | 0.7× | n/a | 0.7× | 1.91 |
| SAB Biotherapeutics, Inc. · NASDAQ:SABS | US$255.7M | US$156.5M | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 1.19 |
| Evommune, Inc. · NYSE:EVMN | US$255.5M | US$86.86M | n/a | n/a | n/a | 1.0× | n/a | 0.0× | 0.96 |
| Editas Medicine, Inc. · NASDAQ:EDIT | US$253.1M | US$119.7M | n/a | 2.4× | n/a | 3.0× | −144.9% | 0.7× | 2.22 |
| Median of the others | US$257.8M | US$119.4M | 6.3× | 2.0× | −196.0% | 0.1× | 1.52 |
Forecasts
5 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 22, 2026. Not 6ix's view and not investment advice.
- Price target
- 12.17 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.20 · 6 analysts
- Revenue, year to Dec 2026
- 5.99M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Shankar Musunuri | Chairman of the Board, CEO and Co-founder |
| Rita Johnson-Greene | Chief Financial Officer |
| Abhi Gupta | Executive Vice President, Commercial and Business Development |
| Chris Clark | VP Communications |
| Paul Staid | Executive Vice President, Operations |
| Tiffany Hamilton | AVP, Head of Communications |
| Arun Upadhyay | Chief Scientific Officer, Head of Research & Development |
| Mohamed Genead | Chief Medical Officer |
| Uday B. Kompella | Co-founder and Director |
| Vijay Tammara | Chief Development Officer |
Board
| Director | Role |
|---|---|
| Shankar Musunuri | Chairman of the Board, CEO and Co-founder |
| Blaise Coleman | Director |
| John Zhang | Director |
| Junge Zhang | Director |
| Kirsten Castillo | Director |
| Satish Chandran | Director |
| Uday B. Kompella | Co-founder and Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Ocugen (NASDAQ:OCGN) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 8:30 AM ET | Replay |
| Ocugen (NASDAQ:OCGN) Q2 2026 Earnings Call | Thu, Aug 06, 2026 · 8:30 AM ET | Replay |
| Ocugen (NASDAQ:OCGN) Q1 2026 Earnings Call | Tue, May 05, 2026 · 8:30 AM ET | Replay |
| Ocugen (NASDAQ:OCGN) Q4 2025 Earnings Call | Wed, Mar 04, 2026 · 8:30 AM ET | Replay |
| Ocugen (NASDAQ:OCGN) Q3 2025 Earnings Call | Wed, Nov 05, 2025 · 8:30 AM ET | Replay |
| Ocugen (NASDAQ:OCGN) Q2 2025 Earnings Call | Fri, Aug 01, 2025 · 8:30 AM ET | Replay |
| Ocugen (NASDAQ:OCGN) Q1 2025 Earnings Call | Fri, May 09, 2025 · 8:30 AM ET | Replay |
| Ocugen (NASDAQ:OCGN) Q4 2024 Earnings Call | Wed, Mar 05, 2025 · 8:30 AM ET | Replay |
| Ocugen (NASDAQ:OCGN) Q3 2024 Earnings Call | Fri, Nov 08, 2024 · 8:30 AM ET | Replay |
| Ocugen (NASDAQ:OCGN) Q2 2024 Earnings Call | Thu, Aug 08, 2024 · 8:30 AM ET | Replay |
All 23 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | +17.4% |
| Q2 2026 | Aug 6, 2026 · Before open | −3.1% |
| Q1 2026 | May 5, 2026 · After close | −2.4% |
| Q4 2025 | Mar 27, 2026 | −10.7% |
| Q3 2025 | Nov 5, 2025 · Before open | −1.4% |
| Q2 2025 | Aug 1, 2025 · After close | +0.6% |
| Q1 2025 | May 9, 2025 · Before open | −2.8% |
| Q4 2024 | Mar 31, 2025 · Before open | −11.7% |
| Q3 2024 | Nov 14, 2024 · After close | −6.1% |
| Q2 2024 | Aug 8, 2024 · Before open | +8.5% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | −6.1% |
| Q4 2023 | Feb 7, 2024 · Before open | +1.5% |
| Q3 2023 | Nov 9, 2023 · Before open | −4.1% |
| Q2 2023 | Aug 21, 2023 · After close | −9.0% |
| Q1 2023 | May 5, 2023 · Before open | +0.7% |
| Q4 2022 | Feb 28, 2023 · Before open | +2.1% |
| Q3 2022 | Nov 8, 2022 · Before open | +7.2% |
| Q2 2022 | Aug 5, 2022 · Before open | +3.3% |
| Q1 2022 | May 6, 2022 · Before open | −5.3% |
| Q4 2021 | Feb 25, 2022 · Before open | +5.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 16 slides | Nov 4, 2026 |
| Investor Presentation (October 2026) | Investor deck | 32 slides | Oct 15, 2026 |
| Investor Presentation (September 2026) | Investor deck | 28 slides | Sep 8, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 11 slides | Aug 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 20 slides | May 5, 2026 |
| Investor Presentation (March 2026) | Investor deck | 33 slides | Mar 27, 2026 |
| Investor Presentation (March 2026) | Investor deck | 35 slides | Mar 24, 2026 |
| Technical Presentation (March 2026) | Technical | 14 slides | Mar 24, 2026 |
| Q4 2025 Earnings Presentation | Earnings | 25 slides | Mar 4, 2026 |
| Investor Presentation (January 2026) | Investor deck | 37 slides | Jan 15, 2026 |
Show 50 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2025 Earnings Presentation | Earnings | 15 slides | Nov 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 18 slides | Aug 1, 2025 |
| BIO 2025 | Conference | 20 slides | Jun 17, 2025 |
| Q1 2025 Earnings Presentation | Earnings | 21 slides | May 9, 2025 |
| Eyecelerator May 2025 | Conference | 17 slides | May 1, 2025 |
| Conference Presentation (April 2025) | Conference | 21 slides | Apr 4, 2025 |
| FY2024 Earnings Presentation | Earnings | 22 slides | Mar 5, 2025 |
| Investor Presentation (March 2025) | Investor deck | 32 slides | Mar 3, 2025 |
| Investor Presentation (February 2025) | Investor deck | 28 slides | Feb 12, 2025 |
| Investor Presentation (January 2025) | Investor deck | 27 slides | Jan 29, 2025 |
| Investor Presentation (December 2024) | Investor deck | 25 slides | Dec 3, 2024 |
| Investor Day (November 2024) | Investor day | 49 slides | Nov 12, 2024 |
| Q3 2024 Earnings Presentation | Earnings | 14 slides | Nov 8, 2024 |
| Investor Presentation (August 2024) | Investor deck | 21 slides | Aug 13, 2024 |
| Q2 2024 Earnings Presentation | Earnings | 15 slides | Aug 8, 2024 |
| Q1 2024 Earnings Presentation | Earnings | 16 slides | May 14, 2024 |
| FY2023 Earnings Presentation | Earnings | 11 slides | Apr 2, 2024 |
| Investor Day (February 2024) | Investor day | 27 slides | Feb 21, 2024 |
| Investor Presentation (November 2023) | Investor deck | 23 slides | Nov 9, 2023 |
| Q3 2023 Earnings Presentation | Earnings | 19 slides | Nov 9, 2023 |
| Technical Presentation (September 2023) | Technical | 16 slides | Sep 13, 2023 |
| Q2 2023 Earnings Presentation | Earnings | 14 slides | Aug 22, 2023 |
| BIO International 2023 | Conference | 14 slides | Jun 5, 2023 |
| Investor Presentation (May 2023) | Investor deck | 23 slides | May 5, 2023 |
| Q1 2023 Earnings Presentation | Earnings | 18 slides | May 5, 2023 |
| Corporate Update (April 2023) | Corporate update | 12 slides | Apr 14, 2023 |
| Investor Presentation (March 2023) | Investor deck | 25 slides | Mar 13, 2023 |
| FY2022 Earnings Presentation | Earnings | 13 slides | Feb 28, 2023 |
| Investor Presentation (February 2023) | Investor deck | 25 slides | Feb 6, 2023 |
| Investor Presentation (January 2023) | Investor deck | 26 slides | Jan 9, 2023 |
| Investor Presentation (November 2022) | Investor deck | 25 slides | Nov 8, 2022 |
| Q3 2022 Earnings Presentation | Earnings | 14 slides | Nov 8, 2022 |
| Technical Presentation (November 2022) | Technical | 35 slides | Nov 1, 2022 |
| Investor Day (November 2022) | Investor day | 9 slides | Nov 1, 2022 |
| Investor Presentation (August 2022) | Investor deck | 23 slides | Aug 26, 2022 |
| Investor Presentation (August 2022) | Investor deck | 21 slides | Aug 17, 2022 |
| Investor Presentation (August 2022) | Investor deck | 25 slides | Aug 16, 2022 |
| Q2 2022 Earnings Presentation | Earnings | 10 slides | Aug 5, 2022 |
| Investor Presentation (May 2022) | Investor deck | 17 slides | May 6, 2022 |
| Q1 2022 Earnings Presentation | Earnings | 9 slides | May 6, 2022 |
This page holds 50 of 75 decks. Open Decks
Financings
| Raise | Date |
|---|---|
| 6.75% convertible senior notes due 2034 Update: US$115M–US$130M Use of proceeds: $32.7 million to retire the Avenue debt; remaining net proceeds for general corporate purposes | May 5, 2026 |
| Public offering of common stock Announced: US$22.5M · US$1.5 a share · Oppenheimer & Co. Dealers: Oppenheimer & Co. (lead) Buyers: RTW Investments Use of proceeds: General corporate purposes, capital expenditures, working capital, and general and administrative expenses | Jan 21, 2026 |
| Registered direct offering of common stock and warrants Closed: US$20M raised · US$1 a share · Warrants at US$1.5 for 24 months · Noble Capital Markets, Inc. +2 Dealers: Noble Capital Markets, Inc. (lead), Maxim Group LLC, Titan Partners Group Buyers: Janus Henderson Investors (20,000,000 shares of common stock and warrants to purchase up to 20,000,000 shares) Use of proceeds: Extend the company's cash runway into the second quarter of 2026 | Aug 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as HISTOGENICS CORP. Priced at US$11.00 a share on Dec 2, 2014.
- Price
- US$11.00 a share
- Shares offered
- 5,909,091 shares of common stock
- Offering size
- US$65 million
- Underwriters
- Cowen and Company, Needham & Company, Canaccord Genuity, BTIG · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 14, 2014 |
| Filed publicly | Oct 7, 2014 |
| Amended 4 times | Newest Dec 2, 2014 |
| Shares registered with an exchange | Nov 18, 2014 |
| Declared effective by the SEC | Dec 2, 2014 |
| Final prospectus, with the price | Dec 3, 2014 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 3, 2014 |
| EFFECT · Notice that a registration is effective | Dec 2, 2014 |
| S-1/A · Registration statement, amended | Dec 2, 2014 |
| CERTNAS · Nasdaq's certificate of listing | Dec 1, 2014 |
| CORRESP · Letter to the SEC | Nov 28, 2014 |
| CORRESP · Letter to the SEC | Nov 28, 2014 |
| FWP · Free writing prospectus | Nov 26, 2014 |
| S-1/A · Registration statement, amended | Nov 26, 2014 |
| 8-A12B · Registration of shares for listing on an exchange | Nov 18, 2014 |
| S-1/A · Registration statement, amended | Nov 14, 2014 |
All 24 filings
| Filing | Filed |
|---|---|
| S-1/A · Registration statement, amended | Nov 7, 2014 |
| CORRESP · Letter to the SEC | Oct 27, 2014 |
| CORRESP · Letter to the SEC | Oct 24, 2014 |
| CORRESP · Letter to the SEC | Oct 23, 2014 |
| S-1 · Registration statement | Oct 7, 2014 |
| DRS/A · Draft registration statement, amended | Oct 6, 2014 |
| DRS/A · Draft registration statement, amended | Jul 11, 2014 |
| UPLOAD · Letter from the SEC | Jun 4, 2014 |
| DRS/A · Draft registration statement, amended | May 16, 2014 |
| UPLOAD · Letter from the SEC | Apr 25, 2014 |
| DRS/A · Draft registration statement, amended | Apr 11, 2014 |
| DRS/A · Draft registration statement, amended | Mar 20, 2014 |
| UPLOAD · Letter from the SEC | Mar 13, 2014 |
| DRS · Draft registration statement | Feb 14, 2014 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 3, 2014
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.41M | 4.05M | 6.04M | 2.49M | 0 | 43.0K | 0 | 0 | 0 | 0 |
| Cost of revenue | 2.39M | 1.97M | 704.0K | 1.07M | 589.0K | 6.35M | 8.09M | 49.6K | 1.53M | 1.67M |
| Gross profit | 2.02M | 2.09M | 5.33M | -1.07M | -589.0K | -6.31M | -8.09M | -49.6K | -1.53M | -1.67M |
| Research and development | 39.8M | 32.1M | 39.6M | 56.2M | 35.1M | 6.35M | 8.09M | 10.3M | 15.6M | 21.6M |
| Selling, general and administrative | 27.6M | 26.7M | 32.0M | 35.1M | 22.9M | 7.97M | 6.08M | 10.2M | 9.38M | 8.53M |
| Operating income | -62.9M | -54.8M | -65.5M | -89.1M | -58.0M | -21.3M | -14.2M | -16.1M | -24.9M | -30.3M |
| Depreciation and amortization | 2.40M | 1.90M | 700.0K | 480.0K | 229.0K | 100.0K | 100.0K | 49.6K | 1.53M | 1.67M |
| EBITDA | -60.5M | -52.9M | -64.8M | -88.6M | -57.8M | -21.2M | -14.1M | -16.1M | -23.4M | -28.6M |
| Interest expense | 5.19M | 688.0K | 3.52M | 79.0K | 721.0K | 1.77M | 3.75M | 134.0K | 60.0K | |
| Income before tax | -67.8M | -54.1M | -63.1M | -86.8M | -58.4M | -21.8M | -20.2M | -8.64M | -26.4M | -16.2M |
| Income tax | 0 | 0 | 0 | 0 | -52.0K | 0 | 0 | -15.8M | -186.0K | -15.8M |
| Net income | -67.8M | -54.1M | -63.1M | -86.8M | -58.4M | -21.8M | -20.2M | -18.2M | -26.4M | -16.2M |
| Earnings per share, basic | -0.22 | -0.19 | -0.26 | -0.40 | -0.30 | -0.31 | -1.46 | -0.23 | -0.99 | -0.97 |
| Earnings per share, diluted | -0.26 | -0.40 | -0.30 | -0.31 | -1.46 | -0.79 | -0.99 | -2.18 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 18.6M | 58.5M | 39.5M | 77.6M | 95.0M | 24.0M | 7.44M | 1.63M | 7.08M | 31.9M |
| Short-term investments | 0 | 0 | 13.4M | 0 | 0 | 900.0K | ||||
| Receivables | 4.99M | |||||||||
| Inventory | 4.99M | |||||||||
| Current assets | 24.3M | 61.7M | 43.0M | 98.5M | 102.6M | 25.9M | 15.8M | 1.94M | 8.18M | 32.1M |
| Property, plant and equipment | 14.4M | 16.6M | 17.3M | 6.05M | 1.16M | 633.0K | 222.5K | 245.8K | 2.72M | 3.86M |
| Total assets | 43.5M | 82.4M | 64.5M | 108.6M | 105.8M | 27.4M | 16.8M | 2.45M | 11.0M | 36.1M |
| Accounts payable | 6.20M | 4.24M | 3.17M | 8.06M | 2.31M | 395.0K | 1.90M | 3.28M | 776.0K | 1.59M |
| Current liabilities | 23.0M | 21.6M | 17.1M | 28.5M | 7.00M | 3.61M | 4.54M | 14.1M | 3.81M | 5.17M |
| Long-term debt | 27.5M | 27.3M | 2.80M | 2.29M | 1.71M | 1.82M | 1.07M | 1.02M | 961.7K | 178.0K |
| Total debt | 28.8M | 28.7M | 2.80M | 2.29M | 1.71M | 2.29M | 1.07M | 8.50M | 178.0K | 761.0K |
| Total liabilities | 55.7M | 52.8M | 24.0M | 34.7M | 9.94M | 5.83M | 5.79M | 15.2M | 22.3M | 22.5M |
| Shareholders' equity | -12.2M | 29.6M | 40.6M | 74.0M | 91.2M | 21.6M | 11.0M | -12.7M | 4.43M | 13.6M |
| Shares outstanding | 312.4M | 291.4M | 256.6M | 221.6M | 199.4M | 184.0M | 52.6M | 4.96M | 24.6M | 20.6M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -57.0M | -42.1M | -62.1M | -60.1M | -47.9M | -14.7M | -16.9M | -11.6M | -23.0M | -25.7M |
| Capital spending | -185.0K | -3.38M | -10.5M | -4.46M | -939.0K | -307.0K | -30.0K | -77.4K | -276.0K | -320.0K |
| Free cash flow | -57.1M | -45.5M | -72.5M | -64.5M | -48.9M | -15.0M | -16.9M | -11.7M | -23.3M | -26.1M |
| Cash from investing | -311.0K | -3.38M | 3.08M | -17.0M | -1.82M | -307.0K | -2.36M | -77.4K | -1.23M | -320.0K |
| Cash from financing | 17.3M | 64.9M | 20.9M | 59.5M | 120.7M | 31.6M | 25.1M | 7.18M | -577.0K | 27.0M |
| Dividends paid | -6.80M | |||||||||
| Share buybacks | 0 | 0 | -48.0K | 0 | 6.00K | 27.6M | ||||
| Change in cash | -39.9M | 19.4M | -38.1M | -17.5M | 70.9M | 16.6M | 5.82M | -4.52M | -24.8M | 993.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 10, 2026 | Material contract | SEC |
| DEFA14A · Additional proxy material | Nov 6, 2026 | Meeting notice | SEC |
| DEFA14A · Additional proxy material | Nov 6, 2026 | Meeting notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 8-K · Current report | Oct 15, 2026 | Current report | SEC |
| 8-K · Current report | Oct 14, 2026 | Material contract | SEC |
| 4 · Change in ownership | Oct 13, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 9, 2026 | Other filings | SEC |
| 8-K · Current report | Oct 5, 2026 | Meeting outcome | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Sep 22, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Sep 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2026 | Other filings | SEC |
| 8-K · Current report | Sep 8, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Aug 13, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 7, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Jul 30, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Jul 30, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 29, 2026 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Jul 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jul 13, 2026 | Current report | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 15, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2026 | Meeting outcome | SEC |
| 8-K · Current report | Jun 3, 2026 | Management or board change | SEC |
| 8-K · Current report | May 14, 2026 | Management or board change | SEC |
| 8-K · Current report | May 14, 2026 | Financing | SEC |
| 10-Q · Quarterly report | May 7, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2026 | Results | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 8-K · Current report | May 4, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| PRER14A | Apr 20, 2026 | Other filings | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 14, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 26, 2026 | Current report | SEC |
| 8-K · Current report | Mar 24, 2026 | Current report | SEC |
| 8-K · Current report | Mar 20, 2026 | Current report | SEC |
| 3 · Initial statement of ownership | Mar 5, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Mar 4, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 4, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 4, 2026 | Current report | SEC |
| 8-K · Current report | Mar 4, 2026 | Results | SEC |
| 8-K · Current report | Feb 9, 2026 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 23, 2026 | Current report | SEC |
| 8-K · Current report | Jan 21, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jan 21, 2026 | Offer document | SEC |
| 8-K · Current report | Jan 15, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 18, 2025 | Management or board change | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 8, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 31, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 18, 2025 | Current report | SEC |
| 8-K · Current report | Sep 15, 2025 | Material contract | SEC |
| 8-K · Current report | Sep 5, 2025 | Material contract | SEC |
| 8-K · Current report | Aug 11, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Aug 11, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 4, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 1, 2025 | Results | SEC |
| 8-K · Current report | Jul 30, 2025 | Current report | SEC |
| 8-K · Current report | Jul 29, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 17, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 9, 2025 | Other filings | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| 8-K · Current report | Jun 23, 2025 | Material contract | SEC |
| 8-K · Current report | Jun 16, 2025 | Current report | SEC |
| 3/A · Initial statement of ownership, amended | Jun 12, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 11, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 9, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2025 | Meeting outcome | SEC |
| 8-K · Current report | May 9, 2025 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 1, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 25, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 25, 2025 | Management or board change | SEC |
| 8-K · Current report | Apr 4, 2025 | Current report | SEC |
| S-8 · Registration statement for employee plans | Mar 5, 2025 | Offer document | SEC |
| 10-K · Annual report | Mar 5, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2025 | Results | SEC |
| 8-K · Current report | Mar 3, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Feb 14, 2025 | Other filings | SEC |
| 8-K · Current report | Feb 12, 2025 | Current report | SEC |
| CORRESP · Letter to the SEC | Feb 11, 2025 | Other filings | SEC |
| 8-K/A · Current report, amended | Feb 7, 2025 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Feb 6, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 5, 2025 | Big-stake notice | SEC |
| S-3 · Registration statement | Jan 31, 2025 | Offer document | SEC |
| 8-K · Current report | Jan 29, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 3, 2025 | Current report | SEC |
| 8-K · Current report | Dec 3, 2024 | Current report | SEC |
| 4 · Change in ownership | Dec 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 26, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 15, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 15, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| 8-K · Current report | Nov 8, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Nov 8, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 8, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 22, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Oct 16, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 26, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 16, 2024 | Other filings | SEC |
| 8-K · Current report | Aug 13, 2024 | Current report | SEC |
| 8-K · Current report | Aug 8, 2024 | Results | SEC |
| 10-Q · Quarterly report | Aug 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2024 | Current report | SEC |
| 424B5 · Prospectus | Aug 1, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 1, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Jul 31, 2024 | Offer document | SEC |
| 8-K · Current report | Jul 8, 2024 | Current report | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 2, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 28, 2024 | Meeting outcome | SEC |
| DEFA14A · Additional proxy material | Jun 18, 2024 | Meeting notice | SEC |
| 8-K · Current report | Jun 6, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | May 28, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | May 28, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | May 17, 2024 | Meeting notice | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-A12G · Registration of a class of shares | May 10, 2024 | Other filings | SEC |
| 8-K · Current report | May 10, 2024 | Current report | SEC |
| EFFECT · Notice that a registration is effective | May 2, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Apr 29, 2024 | Other filings | SEC |
| 10-K/A · Annual report, amended | Apr 29, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 29, 2024 | Current report | SEC |
| UPLOAD · Letter from the SEC | Apr 25, 2024 | Other filings | SEC |
| S-3 · Registration statement | Apr 17, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | Apr 17, 2024 | Offer document | SEC |
| 4 · Change in ownership | Apr 17, 2024 | Insider trade | SEC |
| 10-K · Annual report | Apr 16, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 8, 2024 | Current report | SEC |
| 8-K · Current report | Apr 2, 2024 | Results | SEC |
| 8-K · Current report | Apr 1, 2024 | Current report | SEC |
| NT 10-K · Late filing notice | Apr 1, 2024 | Explanation request | SEC |
| 8-K · Current report | Mar 21, 2024 | Current report | SEC |
| 3 · Initial statement of ownership | Mar 20, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Mar 20, 2024 | Management or board change | SEC |
| 8-K · Current report | Mar 18, 2024 | Current report | SEC |
| 8-K · Current report | Feb 21, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 22, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 8, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 8-K · Current report | Dec 22, 2023 | Current report | SEC |
| 8-K · Current report | Nov 9, 2023 | Current report | SEC |
| 8-K · Current report | Nov 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 1, 2023 | Current report | SEC |
| UPLOAD · Letter from the SEC | Oct 12, 2023 | Other filings | SEC |
| 8-K · Current report | Oct 10, 2023 | Current report | SEC |
| CORRESP · Letter to the SEC | Oct 4, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 19, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Sep 19, 2023 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Sep 19, 2023 | Other filings | SEC |
| 8-K · Current report | Sep 13, 2023 | Current report | SEC |
| 8-K · Current report | Aug 22, 2023 | Results | SEC |
| 8-K · Current report | Aug 21, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 21, 2023 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 15, 2023 | Explanation request | SEC |
| 8-K · Current report | Aug 15, 2023 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 7, 2023 | Big-stake notice | SEC |
This page holds 200 of 895 filings. Open Filings
Cap table
Built by 6ix from Ocugen, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 339,306,603
- Fully diluted
- 339,306,603
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 339,306,603 | Oct 30, 2026 |
Warrants and options
| Lot |
|---|
| Warrants · US$1.50 · expire about Aug 2027 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 339,306,603 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| John H. Johnson Other companies: Xeris Biopharma Holdings, Inc. (Independent, Non-executive Board Member · Since at least Oct 5, 2021); Axogen, Inc. (Director · Since at least Jul 19, 2021); Verastem, Inc. (Director · Since at least Apr 23, 2020); Applied Therapeutics Inc (Executive Chairman, Director · Dec 19, 2024 – Dec 19, 2024 · Past); Melinta Therapeutics Inc (Chief Executive Officer, Director · Jun 12, 2018 – Jun 27, 2019 · Past); AVEO Pharmaceuticals Inc (Director · Feb 1, 2018 – Feb 1, 2018 · Past); Strongbridge Biopharma plc (Chief Executive Officer, Director · Jan 1, 2018 – Oct 5, 2021 · Past); Cempra Inc (Director · Jan 3, 2017 – Jan 3, 2017 · Past); Portola Pharmaceuticals Inc (Director · Jun 17, 2016 – Jul 2, 2020 · Past); Sucampo Pharmaceuticals Inc (Director · Jun 2, 2016 – Feb 13, 2018 · Past) | Director · Dec 16, 2016 – Jun 15, 2018 · Past |
| David Gill Other companies: Telix Pharmaceuticals Limited (Chair & Independent Non-Executive Director · Since Apr 2, 2026); Y mAbs Therapeutics (Director · Since at least Sep 20, 2018); Evolus, Inc. Common Stock (Director · Since at least Feb 12, 2018); Strongbridge Biopharma plc (Director · Sep 3, 2019 – Oct 5, 2021 · Past); STRATA Skin Sciences, Inc. (Director · May 30, 2018 – Nov 22, 2019 · Past); Melinta Therapeutics Inc (Director · May 25, 2018 – Jun 11, 2019 · Past); Cempra Inc (Director · Jan 1, 2016 – Jan 3, 2017 · Past); EndoChoice Holdings Inc (President and CFO · Aug 14, 2015 – Nov 22, 2016 · Past) | Director · Dec 9, 2016 – Jun 15, 2018 · Past |
| Kevin Rakin Other companies: Elutia, Inc. (Chairman · Since at least Oct 7, 2020); Quantum-Si Incorporated (Director · Since at least Sep 3, 2020); Oramed Pharmaceuticals Inc. (Director · Aug 30, 2016 – Mar 21, 2022 · Past) | Director · Dec 2, 2014 – Feb 8, 2019 · Past |
| Marna C Whittington Other companies: Phillips 66 (Director · Since at least May 9, 2012); Brookfield Oaktree Holdings, LLC (Director · Jun 28, 2012 – Sep 30, 2019 · Past); Macy's Inc (Director · Sep 30, 2011 – May 21, 2021 · Past) | Director · Mar 21, 2022 – Jun 28, 2024 · Past |
| Lynne E Kelley Other companies: X4 Pharmaceuticals, Inc. (See Remarks · Apr 24, 2019 – Apr 24, 2019 · Past); Senseonics Holdings, Inc. (Chief Medical Officer · Mar 17, 2016 – Feb 2, 2018 · Past) | Chief Medical Officer · Jul 31, 2018 – Oct 1, 2018 · Past |
| Prabhavathi Fernandes Other companies: CapForce Inc. (Director · Apr 1, 2020 – Jun 7, 2023 · Past); Cempra Inc (President and CEO, Director · Feb 2, 2012 – Jan 1, 2016 · Past) | Director · Apr 5, 2020 – Nov 26, 2024 · Past |
| Quan Vu Other companies: Monopar Therapeutics Inc. (Chief Financial Officer, Principal Accounting Officer, and Principal Financial Officer · Since at least Mar 3, 2025); Forum Markets, Incorporated (COO / Chief Business Officer · Oct 29, 2021 – Dec 16, 2021 · Past) | CFO/CBO · Mar 6, 2023 – Mar 6, 2023 · Past |
| Sanjay Subramanian Other companies: Scynexis, Inc. (Chief Financial Officer · Since at least Sep 9, 2026); Inozyme Pharma Inc (SVP, CFO & Head of BD · Since at least Mar 21, 2022) | Chief Financial Officer · Oct 1, 2019 – Jan 3, 2022 · Past |
| Satishchandran Chandrasekhar Other companies: Statera Biopharma, Inc. (Director · Feb 22, 2022 – Feb 22, 2022 · Past); Marizyme, Inc. (Chief Operating Officer · Jul 31, 2020 – Jul 31, 2020 · Past) | Director · Since at least Jun 5, 2025 |
| Blaise Coleman Other companies: Endo International PLC (President, CEO, Director · Nov 22, 2016 – Mar 29, 2022 · Past) | Director · Since at least Jun 5, 2025 |
All 44 people
| Person | Seat |
|---|---|
| David C. Hood Other companies: Fathom Holdings Inc. (Director · Since at least Jul 28, 2020) | Director · Jul 19, 2019 – Jul 19, 2019 · Past |
| Frank Leo Other companies: Rxelite Inc (Director · Feb 13, 2008 – Jun 4, 2008 · Past) | Director · Sep 27, 2019 – Jan 2, 2020 · Past |
| Kirsten Castillo Other companies: ACV Auctions Inc. (Director · Since at least Mar 23, 2021) | Director · Since at least Apr 5, 2020 |
| Abhi Gupta | Executive Vice President, Commercial and Business Development · Since at least Sep 30, 2026 |
| Arun Upadhyay | Chief Scientific Officer, Head of Research & Development · Since at least Jan 1, 2023 |
| Chris Clark | VP Communications · Since at least Oct 22, 2026 |
| Daniel Jorgensen | Chief Medical Officer · Sep 27, 2019 – May 5, 2020 · Past |
| Donald Haut | Chief Business Officer · Jun 5, 2017 – Oct 1, 2018 · Past |
| Gloria Matthews | Chief Medical Officer · Jul 14, 2015 – Feb 14, 2017 · Past |
| Huma Qamar | Chief Medical Officer · Mar 18, 2024 – Jan 2, 2025 · Past |
| Jessica Crespo | CAO/SVP, Finance · Jan 3, 2023 – Jan 3, 2023 · Past |
| John Zhang | Director · Since at least Nov 5, 2026 |
| Jolanda Crombach | General Manager of the Company’s European affiliate · Oct 6, 2026 – Nov 5, 2026 · Past |
| Junge Zhang | Director · Since at least Sep 27, 2019 |
| Kevin McArdle | Chief Financial Officer · Dec 2, 2014 – Feb 26, 2015 · Past |
| Manish Potti | Director · Sep 27, 2019 – Dec 16, 2021 · Past |
| Michael Breininger | See Remarks · Sep 15, 2023 – Sep 15, 2023 · Past |
| Michael Lewis | Director · Dec 2, 2014 – Feb 8, 2019 · Past |
| Mohamed Genead | Chief Medical Officer · Since at least Sep 1, 2026 |
| Nancy Lynch | Chief Medical Officer · Dec 2, 2014 – Dec 2, 2014 · Past |
| Paul Staid | Executive Vice President, Operations · Since at least Nov 4, 2026 |
| Ramesh Kumar | Director · Sep 27, 2019 – Jun 9, 2023 · Past |
| Ramesh Ramachandran | Chief Accounting Officer · Since at least Nov 14, 2024 |
| Rasappa Arumugham | Chief Scientific Officer · Sep 27, 2019 – May 5, 2020 · Past |
| Rita Johnson-Greene | Chief Financial Officer · Since at least Feb 9, 2026 |
| Satish Chandran | Director · Since at least Nov 5, 2026 |
| Shankar Musunuri | Chairman of the Board, CEO and Co-founder · Since at least Sep 27, 2019 |
| Stephen Richard Kennedy | Chief Operating Officer · Feb 14, 2017 – Oct 1, 2018 · Past |
| Suha Taspolatoglu | Director · Jan 1, 2021 – Jan 1, 2021 · Past |
| Susan B Washer | Director · Apr 16, 2018 – Apr 16, 2018 · Past |
| Tiffany Hamilton | AVP, Head of Communications · Since at least Apr 29, 2026 |
| Treerita Essalima Johnson-Greene | Chief Financial Officer · Since at least Mar 4, 2026 |
| Uday B. Kompella | Co-founder and Director · Since at least Sep 27, 2019 |
| Vijay Tammara | Chief Development Officer · Since at least Sep 27, 2019 |
Log in to ask 6ix AI your own questions about Ocugen, Inc.